A physician reported via a sales representative that a (b)(6) male received solesta (dextranomer/hyaluronic acid) injection into the submucosa of the anal canal as treatment for "horrible" fecal incontinence.Additional medical history included that solesta was considered the "last resort" before having to perform a colostomy.Concurrent medications were not provided.On (b)(6) 2014, the patient received solesta.No antibiotics were administered prophylactically.The patient began having symptoms of an infection soon after solesta injection (timeframe not indicated).He was diagnosed with an abscess and antibiotics were started.The patient did not improve and was evaluated by a gastrointestinal specialist.A flexible sigmoidoscopy was performed; however, the abscess was not drained.The patient was still not improving, so he was seen by a surgeon who observed the infection to be tracking into the patient's pelvis.The patient was taken to the operating room and a colostomy was performed.At the time of this report, the patient was stable and recovering from the events.Causality was not reported.The company felt the events were possibly related to solesta.
|
The limited information about the patient's possible underlying condition makes a causality assessment difficult, however, a causality cannot be excluded.The injection procedure per se and the fact that no prophylactic antibiotics were provided may have contributed to the events.
|